Skip to content

Study · Non-randomized trial · n = 54 · 2019

9 results

Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients.

Deng H, Lin S, Yang X, Lv J, Luo S, Zeng L, Weng J, Xu W

Journal of diabetes1 Jan 2019Cited by 12 (Europe PMC)

PMID30520243 (opens in a new tab)PMCIDPMC6850147 (opens in a new tab)DOI10.1111/1753-0407.12883 (opens in a new tab)PepBankPUB-30520243
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In overweight patients with newly diagnosed T2D, exenatide reduced HbA1c from baseline.

    In plain wordsIn overweight patients with newly diagnosed T2D, exenatide reduced HbA1c from baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c in overweight patients
    Study

    n = 54

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.8%
    overweight

    Source sentences

    Summary
    After 48-week treatment, the estimated mean changes in HbA1c in normal-weight, overweight, and obese patients were -1.9%, -1.8%, and -1.5%, respectively (P = 0.290 among groups after adjustment for baseline values).
    1 context sentence
    Summary · context
    In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    In normal-weight patients with newly diagnosed T2D, exenatide reduced HbA1c from baseline.

    In plain wordsIn normal-weight patients with newly diagnosed T2D, exenatide reduced HbA1c from baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c in normal-weight patients
    Study

    n = 29

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.9%
    normal-weight

    Source sentences

    Summary
    After 48-week treatment, the estimated mean changes in HbA1c in normal-weight, overweight, and obese patients were -1.9%, -1.8%, and -1.5%, respectively (P = 0.290 among groups after adjustment for baseline values).
    1 context sentence
    Summary · context
    In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks.
  3. 03HumanNon-randomized trialEfficacy outcome

    In obese patients with newly diagnosed T2D, exenatide reduced HbA1c from baseline.

    In plain wordsIn obese patients with newly diagnosed T2D, exenatide reduced HbA1c from baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c in obese patients
    Study

    n = 27

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.5%
    obese

    Source sentences

    Summary
    After 48-week treatment, the estimated mean changes in HbA1c in normal-weight, overweight, and obese patients were -1.9%, -1.8%, and -1.5%, respectively (P = 0.290 among groups after adjustment for baseline values).
    1 context sentence
    Summary · context
    In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks.
  4. 04HumanNon-randomized trialEfficacy outcome

    In newly diagnosed T2D, HbA1c changes with exenatide did not significantly differ among BMI groups.

    In plain wordsIn newly diagnosed T2D, HbA1c changes with exenatide did not significantly differ among BMI groups.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHbA1c change across BMI groups
    Study

    n: not reported in source

    Comparator
    Other BMI groups
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.9%
    normal-weight
    HbA1c change
    −1.8%
    overweight
    HbA1c change
    −1.5%
    obese

    Source sentences

    Summary
    After 48-week treatment, the estimated mean changes in HbA1c in normal-weight, overweight, and obese patients were -1.9%, -1.8%, and -1.5%, respectively (P = 0.290 among groups after adjustment for baseline values).
    1 context sentence
    Summary · context
    In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks.
  5. 05HumanNon-randomized trialEfficacy outcome

    In newly diagnosed T2D, FPG declines with exenatide were similar among BMI groups.

    In plain wordsIn newly diagnosed T2D, fasting blood sugar declines with exenatide were similar among BMI groups.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeFPG decline across BMI groups
    Study

    n: not reported in source

    Comparator
    Other BMI groups
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    There were similar declines in FPG and 0.5- and 2-hour PPG among groups.
    1 context sentence
    Summary · context
    In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks.
  6. 06HumanNon-randomized trialEfficacy outcome

    In newly diagnosed T2D, 0.5-hour PPG declines with exenatide were similar among BMI groups.

    In plain wordsIn newly diagnosed T2D, blood sugar declines at 0.5-hour after meals were similar among BMI groups with exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant change0.5-hour PPG decline across BMI groups
    Study

    n: not reported in source

    Comparator
    Other BMI groups
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    There were similar declines in FPG and 0.5- and 2-hour PPG among groups.
    1 context sentence
    Summary · context
    In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks.
  7. 07HumanNon-randomized trialEfficacy outcome

    In newly diagnosed T2D, 2-hour PPG declines with exenatide were similar among BMI groups.

    In plain wordsIn newly diagnosed T2D, blood sugar declines at 2-hour after meals were similar among BMI groups with exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant change2-hour PPG decline across BMI groups
    Study

    n: not reported in source

    Comparator
    Other BMI groups
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    There were similar declines in FPG and 0.5- and 2-hour PPG among groups.
    1 context sentence
    Summary · context
    In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks.
  8. 08HumanNon-randomized trialEfficacy outcome

    In newly diagnosed T2D, weight reduction with exenatide showed a nonsignificant increasing trend across BMI groups.

    In plain wordsIn newly diagnosed T2D, weight reduction with exenatide tended to increase across BMI groups, without a significant difference.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeWeight reduction across BMI groups
    Study

    n: not reported in source

    Comparator
    Other BMI groups
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Measurements

    Weight decrease
    2.2 kg
    normal-weight
    Weight decrease
    3.9 kg
    overweight
    Weight decrease
    4 kg
    obese

    Source sentences

    Summary
    There were non-significant trends from normal-weight to overweight to obese patients for increased weight reduction (decreases of 2.2, 3.9, and 4.0 kg, respectively; P = 0.104) and changes in waist circumference (decreases of 2.2, 3.2, and 5.6 cm, respectively; P = 0.078).
    1 context sentence
    Summary · context
    In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks.
  9. 09HumanNon-randomized trialEfficacy outcome

    In newly diagnosed T2D, waist circumference changes with exenatide showed a nonsignificant trend across BMI groups.

    In plain wordsIn newly diagnosed T2D, waist changes with exenatide showed a trend across BMI groups, without a significant difference.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeWaist circumference change across BMI groups
    Study

    n: not reported in source

    Comparator
    Other BMI groups
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Measurements

    Waist decrease
    2.2 cm
    normal-weight
    Waist decrease
    3.2 cm
    overweight
    Waist decrease
    5.6 cm
    obese

    Source sentences

    Summary
    There were non-significant trends from normal-weight to overweight to obese patients for increased weight reduction (decreases of 2.2, 3.9, and 4.0 kg, respectively; P = 0.104) and changes in waist circumference (decreases of 2.2, 3.2, and 5.6 cm, respectively; P = 0.078).
    1 context sentence
    Summary · context
    In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.